NASDAQ · EVGN

EVOGENE Ltd.

$0.52 -$0.02 (-4.15%) 1D Market open

Key Metrics

$6.57M
Market cap
P/E · TTM
$3.85M
Revenue · TTM
−$7.83M
Net income
EPS · TTM $-0.65
Dividend yield
Free cash flow
Beta · 1Y 1.30
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 15
    The stock moved +20.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 15
  • Jul 9
    The stock moved +20.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 9
  • Jun 26
    From its Feb 5 high, the share price fell 65%.

    Peak close $1.10 on Feb 5; trough close $0.39 on Jun 26. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -65%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$6.57M
Enterprise value
Shares outstanding12.1M
52-wk range$0.37 – $1.50
Avg volume · 20D236.3K
Net cash
Book value / share
ExchangeNASDAQ
About EVOGENE Ltd.
IPO dateMar 5, 2008
Employees52

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S1.70
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net -203.1%
FCF
ROE / ROIC — · —

Financial Health

Current ratio
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-06-30 · computed by TickerWolf from SEC filings